CML PT2 Flashcards

1
Q
  • clonal expansion resulting to an increase in one or more myeloid cells
  • lack the philadelphia chromosome
A

bcr;;abl1 negative

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

erythrocytosis but also shows leukocytosis and thrombocytosis

A

polycythemia vera

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

thrombocytosis but can also exhibit leukocytosis with a left shift

A

essential thrombocytopenia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

t/f: bcr;;abl1 gene affects a single lineage

A

false - there might be a tri-lineage proliferation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q
  • initially leukocytosis with a left shift but can also exhibit thrombocytosis
  • slowly develops fibrosis that inhibits hematopoiesis —> pancytopenia
A

primary myelofibrosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

this mutation is necessary in stimulating proliferation and quesence

A

mpl

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

common mutations in bcr;;abl1 gene

A

mpl
jakk2v617f
calr

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

common feature among the 3 conditions

A

thrombocytosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

very common mpn

A

polycythemia vera

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q
  • mild erythrocytosis
  • often asymptomatic and detected incidentally
A

prodromal phase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q
  • proliferative phase
  • hyperviscosity symptoms, thrombotic and hemorrhagic episodes
  • splenomegaly, pruritus, erythromelalgia
A

overt polycythemic phase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q
  • progressive splenomegaly or hypersplenism and pancytopenia
  • post polycythemic myeloid metaplasia –> bone marrow fibrosis, anemia with tear drop cells
A

spent phase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

increase in the actual number of rbc, wbc, and plt resulting from increase in production

A

true pancytosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what mutation is notable in pcv

A

jak2v617f

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

pcv
- initial manifestation of pv
- independent of normal regulatory mechanisms associated with increased red cell mass

A

proliferative phase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

only happens in post polycythemic phase

A

increase reticulin production

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

bone marrow with increased production in all blood cells

A

panmyelosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

in jak2 they control the kinase activity

A

JH1 and JH2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

has the kinase activity

A

jh1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

does not have kinase activity

A

jh2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what jh happens the dimerization of epo

A

jh2 and jh3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what will happen if jak2 is activated

A

it induces phosphorylation of stat proteins

8
Q
  • facilitated by jak2 –> stat protein
  • causes a gene signal for gene expression to promote proliferation, differentiation, maturation, and inhibition of apoptosis
A

phosphorylation

8
Q

valine is released in what domain and converts enzyme to its active form

A

jh2 domain

8
Q
  • confirmational change
  • ducking point, point of dimerization
8
Q

rare in pcv

A

jak2 exon12

8
Q

jak2 exon12 is found in what mpn

A

secondary myelofibrosis

8
Q

high epo levels, no jak2 mutation

A

secondary polycythemia

9
Q
  • normal rbc mass, predominant thrombocytosis
  • jak2 mutation present, but lacks significant erythrocytosis
A

essential thrombocytopenia

9
Q
  • bcr-abl fusion gene
  • leukocytosis with left shift, basophilia, splenomegaly
A

chronic myeloid leukemia

9
Q
  • prominent bone marrow fibrosis
  • leukoerythroblastic reaction in pb
A

primary myelofibrosis

9
Q

goal of theraphy for pcv

A

reduce hyperviscosity

10
Q

treatment of choice for low risk patients in pcv

A

therapeutic phlebotomy

10
Q

treatment for high risk px (young px or women in childbearing age)

A

pegylated ifn-a

11
Q
  • jak2 inhibitor
  • first line of choice following hydroxyurea intolerance of failure
A

ruxolitinib

12
Q
  • epigenetic modifier
  • induces apoptosis in neoplastic cells
A

givinostat

12
Q

clonal mpn:
- increased megakaryopoiesis
- sustained thrombocytosis

A

essential thrombocythemia

12
Q

drivers of acute anemia

A

alkylating agents

13
Q
  • if the clot remains attached to the blood vessel
  • common due to thrombocytosis
  • problem in sustained increase plt count
A

vascular occlusion or hemorrhage

14
Q
  • common in fingers and toes
  • triggered when exposed to cold temp. or stress
  • due to spasms in toes or fingers
A

reynaud syndrome and gout

15
Q

common cause of death in essential thrombocythemia

A

bleeding and thrombosis

15
Q

clonal mpn:
- increased abnormal megakeryocytes and granulocyte
- ineffective hematopoiesis with leukoerythroblastosis

A

primary myelofibrosis

16
Q

serves as a matrix for structural framework in BM

16
Q

the process by which the BM is replaced with connective tissue causing fibrosis

A

myelofibrosis

16
Q

responsible for the production of collagen

A

fibroblast

17
Q

what stain is used in reticulin fibers

A

gomori stain

18
Q

cd marker for hsc and helps strongly in myelofibrosis

19
Q
  • takes a sample of the bm
  • examine the bm architecture, fibrosis, cellularity, etc.
A

bone marrow biopsy

19
Q
  • takes a sample of bone marrow fluid
  • used to analyze individual cells
A

bone marrow aspiration

19
Q

t/f: first line of theraphy in pm works

20
Q

most common cause of death in PM

A

leukemic transformation

21
Q

most common serious infectious agents in CNL

A

mycobacteria and fungi

22
Q

only curative treatment inCNL

A

allogenic stem cell transplantation